Hydrocortison Rompharm (Hydrocortisone)

Hydrocortison Rompharm is employed in clinical practice for conditions where rapid systemic glucocorticoid activity is needed.

• Management of acute adrenal insufficiency or adrenal crisis.
• Treatment of severe asthma or chronic obstructive pulmonary disease exacerbations.
• Adjunct therapy for septic shock and other forms of systemic inflammatory response.
• Rapid control of anaphylaxis or other severe allergic reactions.
• Reduction of postoperative inflammation and edema in surgical patients.

• Hydrocortison Rompharm delivers hydrocortisone, which binds to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating transcription of anti‑inflammatory proteins while suppressing pro‑inflammatory cytokine genes. This genomic effect reduces leukocyte migration, stabilizes lysosomal membranes, and diminishes capillary permeability, producing systemic anti‑inflammatory and immunosuppressive actions.

Hydrocortison Rompharm may cause a range of adverse reactions, varying from mild to severe.

Common

• Transient hyperglycemia or elevated blood glucose levels.
• Mild electrolyte disturbances, such as sodium retention.
• Local irritation at the injection site, including pain or erythema.
• Headache or dizziness.
• Gastrointestinal discomfort, such as nausea.

Serious

• Severe infection due to immunosuppression.
• Acute adrenal suppression or crisis on abrupt discontinuation.
• Significant hypertension or fluid overload.
• Psychiatric disturbances, including mood swings or psychosis.
• Osteonecrosis or rapid bone loss with prolonged use.

When prescribing Hydrocortison Rompharm, clinicians should consider several safety factors.

• Assess for active infections; systemic glucocorticoids can exacerbate bacterial, viral, or fungal diseases.
• Evaluate blood glucose and electrolyte status, especially in diabetic or renal‑impaired patients.
• Use caution in patients with a history of hypertension, heart failure, or peptic ulcer disease.
• Taper the medication gradually after prolonged therapy to avoid adrenal insufficiency.
• Monitor for signs of psychiatric changes, particularly in high‑dose or long‑term regimens.
• Pregnant or breastfeeding women should only use the drug if the potential benefit outweighs the risk.

Hydrocortison Rompharm can influence the activity of several other medicines.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure.
• Combining with other systemic glucocorticoids, which can increase the risk of severe immunosuppression.
• Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients at risk for gastrointestinal bleeding.

Use with caution

• Anticoagulants such as warfarin, as glucocorticoids may enhance anticoagulant effects.
• Antidiabetic agents; hydrocortisone can raise blood glucose, requiring dose adjustments.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.
• Diuretics, because of additive effects on electrolyte balance and blood pressure.